|
1
|
Lee S and Vasudevan S:
Post-transcriptional stimulation of gene expression by microRNAs.
Adv Exp Med Biol. 768:97–126. 2013.PubMed/NCBI
|
|
2
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou P, Xu W, Peng X, et al: Large-scale
screens of miRNA-mRNA interactions unveiled that the 3′UTR of a
gene is targeted by multiple miRNAs. PLoS One. 8:e682042013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM
and Zhang GZ: Biological functions of microRNAs: a review. J
Physiol Biochem. 67:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ebert MS and Sharp PA: Roles for microRNAs
in conferring robustness to biological processes. Cell.
149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Markou A, Liang Y and Lianidou E:
Prognostic, therapeutic and diagnostic potential of microRNAs in
non-small cell lung cancer. Clin Chem Lab Med. 49:1591–1603.
2011.PubMed/NCBI
|
|
7
|
Mulrane L, Klinger R, McGee SF, et al:
MicroRNAs: a new class of breast cancer biomarkers. Expert Rev Mol
Diagn. 14:347–363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pritchard CC, Kroh E, Wood B, et al: Blood
cell origin of circulating microRNAs: a cautionary note for cancer
biomarker studies. Cancer Prev Res (Phila). 5:492–497. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwarzenbach H, Nishida N, Calin GA and
Pantel K: Clinical relevance of circulating cell-free microRNAs in
cancer. Nat Rev Clin Oncol. 11:145–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vasilatou D, Papageorgiou S, Pappa V,
Papageorgiou E and Dervenoulas J: The role of microRNAs in normal
and malignant hematopoiesis. Eur J Haematol. 84:1–16. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang X, Huang H, Li Z, et al: Blockade of
miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for
MLL-associated leukemia. Cancer Cell. 22:524–535. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Watanabe A, Tagawa H, Yamashita J, et al:
The role of microRNA-150 as a tumor suppressor in malignant
lymphoma. Leukemia. 25:1324–1334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao JJ, Lin J, Lwin T, et al: MicroRNA
expression profile and identification of miR-29 as a prognostic
marker and pathogenetic factor by targeting CDK6 in mantle cell
lymphoma. Blood. 115:2630–2639. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He Y, Jiang X and Chen J: The role of
mir-150 in normal and malignant hematopoiesis. Oncogene.
33:3887–3893. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Monticelli S, Ansel KM, Xiao C, et al:
MicroRNA profiling of the murine hematopoietic system. Genome Biol.
6:R712005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Allantaz F, Cheng DT, Bergauer T, et al:
Expression profiling of human immune cell subsets identifies
miRNA-mRNA regulatory relationships correlated with cell type
specific expression. PLoS One. 7:e299792012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de Candia P, Torri A, Pagani M and
Abrignani S: Serum microRNAs as biomarkers of human lymphocyte
activation in health and disease. Front Immunol.
5:432014.PubMed/NCBI
|
|
18
|
Xie SY, Li YJ, Wang PY, Jiao F, Zhang S
and Zhang WJ: MiRNA-regulated expression of oncogenes and tumor
suppressor genes in the cisplatin-inhibited growth of K562 cells.
Oncol Rep. 23:1693–1700. 2010.PubMed/NCBI
|
|
19
|
Fayyad-Kazan H, Bitar N, Najar M, et al:
Circulating miR-150 and miR-342 in plasma are novel potential
biomarkers for acute myeloid leukemia. J Transl Med. 11:312013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ito M, Teshima K, Ikeda S, et al:
MicroRNA-150 inhibits tumor invasion and metastasis by targeting
the chemokine receptor CCR6 in advanced cutaneous T-cell lymphoma.
Blood. 123:1499–1511. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Singh AP, Moniaux N, Chauhan SC, Meza JL
and Batra SK: Inhibition of MUC4 expression suppresses pancreatic
tumor cell growth and metastasis. Cancer Res. 64:622–630. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Andrianifahanana M, Moniaux N, Schmied BM,
et al: Mucin (MUC) gene expression in human pancreatic
adenocarcinoma and chronic pancreatitis: a potential role of MUC4
as a tumor marker of diagnostic significance. Clin Cancer Res.
7:4033–4040. 2001.PubMed/NCBI
|
|
23
|
Chaturvedi P, Singh AP, Moniaux N, et al:
MUC4 mucin potentiates pancreatic tumor cell proliferation,
survival and invasive properties and interferes with its
interaction to extracellular matrix proteins. Mol Cancer Res.
5:309–320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rachagani S, Macha MA, Ponnusamy MP, et
al: MUC4 potentiates invasion and metastasis of pancreatic cancer
cells through stabilization of fibroblast growth factor receptor 1.
Carcinogenesis. 33:1953–1964. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Srivastava SK, Bhardwaj A, Singh S, et al:
MicroRNA-150 directly targets MUC4 and suppresses growth and
malignant behavior of pancreatic cancer cells. Carcinogenesis.
32:1832–1839. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yokobori T, Suzuki S, Tanaka N, et al:
MiR-150 is associated with poor prognosis in esophageal squamous
cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci.
104:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gregory PA, Bert AG, Paterson EL, et al:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thompson EW and Haviv I: The social
aspects of EMT-MET plasticity. Nat Med. 17:1048–1049. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pizzini S, Bisognin A, Mandruzzato S, et
al: Impact of microRNAs on regulatory networks and pathways in
human colorectal carcinogenesis and development of metastasis. BMC
Genomics. 14:5892013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma Y, Zhang P, Wang F, et al: MiR-150 as a
potential biomarker associated with prognosis and therapeutic
outcome in colorectal cancer. Gut. 61:1447–1453. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yong FL, Law CW and Wang CW: Potentiality
of a triple microRNA classifier: miR-193a-3p, miR-23a and
miR-338-5p for early detection of colorectal cancer. BMC Cancer.
13:2802013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ogata-Kawata H, Izumiya M, Kurioka D, et
al: Circulating exosomal microRNAs as biomarkers of colon cancer.
PLoS One. 9:e929212014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Inoue T, Iinuma H, Ogawa E, Inaba T and
Fukushima R: Clinicopathological and prognostic significance of
microRNA-107 and its relationship to DICER1 mRNA expression in
gastric cancer. Oncol Rep. 27:1759–1764. 2012.PubMed/NCBI
|
|
35
|
Katada T, Ishiguro H, Kuwabara Y, et al:
MicroRNA expression profile in undifferentiated gastric cancer. Int
J Oncol. 34:537–542. 2009.PubMed/NCBI
|
|
36
|
Zhou L, Qi X, Potashkin JA, Abdul-Karim FW
and Gorodeski GI: MicroRNAs miR-186 and miR-150 downregulate
expression of the pro-apoptotic purinergic P2×7 receptor by
activation of instability sites at the 3′-untranslated region of
the gene that decrease steady-state levels of the transcript. J
Biol Chem. 283:28274–28286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang S, Chen Y, Wu W, et al: miR-150
promotes human breast cancer growth and malignant behavior by
targeting the pro-apoptotic purinergic P2×7 receptor. PLoS One.
8:P12013.
|
|
38
|
Wu Q, Jin H, Yang Z, et al: MiR-150
promotes gastric cancer proliferation by negatively regulating the
pro-apoptotic gene EGR2. Biochem Biophys Res Commun. 392:340–345.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cheng AM, Byrom MW, Shelton J and Ford LP:
Antisense inhibition of human miRNAs and indications for an
involvement of miRNA in cell growth and apoptosis. Nucleic Acids
Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang PY, Li YJ, Zhang S, et al: Regulating
A549 cells growth by ASO inhibiting miRNA expression. Mol Cell
Biochem. 339:163–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li YJ, Zhang YX, Wang PY, et al:
Regression of A549 lung cancer tumors by anti-miR-150 vector. Oncol
Rep. 27:129–134. 2012.PubMed/NCBI
|
|
42
|
Zhang N, Wei X and Xu L: MiR-150 promotes
the proliferation of lung cancer cells by targeting P53. FEBS Lett.
587:2346–2351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang DT, Ma ZL, Li YL, et al: MiR-150, p53
protein and relevant miRNAs consist of a regulatory network in
NSCLC tumorigenesis. Oncol Rep. 30:492–498. 2013.PubMed/NCBI
|
|
44
|
Cao M, Hou D, Liang H, et al: MiR-150
promotes the proliferation and migration of lung cancer cells by
targeting SRC kinase signalling inhibitor 1. Eur J Cancer.
50:1013–1024. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gu XY, Wang J, Luo YZ, et al:
Down-regulation of miR-150 induces cell proliferation inhibition
and apoptosis in non-small-cell lung cancer by targeting BAK1 in
vitro. Tumour Biol. 35:5287–5293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun Y, Su B, Zhang P, et al: Expression of
miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma
and correlates with clinicopathological features. Oncol Rep.
29:704–712. 2013.PubMed/NCBI
|
|
47
|
Zeng XL, Zhang SY, Zheng JF, Yuan H and
Wang Y: Altered miR-143 and miR-150 expressions in peripheral blood
mononuclear cells for diagnosis of non-small cell lung cancer. Chin
Med J (Engl). 126:4510–4516. 2013.PubMed/NCBI
|
|
48
|
Bi N, Cao J, Song Y, et al: A microRNA
signature predicts survival in early stage small-cell lung cancer
treated with surgery and adjuvant chemotherapy. PLoS One.
9:P12014.
|
|
49
|
Di Masi A, Viganotti M, Antoccia A, et al:
Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell
lines by WNT/β-catenin pathway, microRNA expression and protein
expression profile. Cell Mol Biol (Noisy-le-grand). 56(Suppl):
OL1299–OL1317. 2010.PubMed/NCBI
|
|
50
|
Zhang J, Luo N, Luo Y, Peng Z, Zhang T and
Li S: MicroRNA-150 inhibits human CD133-positive liver cancer stem
cells through negative regulation of the transcription factor
c-Myb. Int J Oncol. 40:747–756. 2012.PubMed/NCBI
|
|
51
|
Weiland M, Gao XH, Zhou L and Mi QS: Small
RNAs have a large impact: circulating microRNAs as biomarkers for
human diseases. RNA Biol. 9:850–859. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lulla RR, Costa FF, Bischof JM, et al:
Identification of differentially expressed microRNAs in
osteosarcoma. Sarcoma. 2011:7326902011.PubMed/NCBI
|
|
53
|
Namløs HM, Meza-Zepeda LA, Barøy T, et al:
Modulation of the osteosarcoma expression phenotype by microRNAs.
PLoS One. 7:e480862012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mosakhani N, Guled M, Leen G, et al: An
integrated analysis of miRNA and gene copy numbers in xenografts of
ewing's sarcoma. J Exp Clin Cancer Res. 31:242012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Magrelli A, Azzalin G, Salvatore M, et al:
Altered microRNA expression patterns in hepatoblastoma patients.
Transl Oncol. 2:157–163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Amaral FC, Torres N, Saggioro F, et al:
MicroRNAs differentially expressed in ACTH-secreting pituitary
tumors. J Clin Endocrinol Metab. 94:320–323. 2009. View Article : Google Scholar : PubMed/NCBI
|
